cece

*February 2021* In EGFR-mutant non–small cell lung cancer (NSCLC) and brain metastases, oral osimertinib (Tagrisso) achieved rapid, high, and uniform brain exposure which was followed reduction in total brain metastases volume, according to results from the phase 1 ODIN-BM study (NCT03463525). A presentation on osimertinib given during the 2020 World…

*February 2021* Highlights from Dr. Collin Blakely's presentation: EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase at the 2021 Targeted Therapies Conference: EGFR C797S is the predominant on-target resistance mutation Osimertinib + gefitinib prevents acquired second-site EGFR resistance mutations in preclinical models 1 st line Osimertinib + Gefitinib is well-tolerated…

*January 2021* The utility of EGFR TKIs in select subgroups of patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), as well as their role in the adjuvant setting, are beginning to be teased out, explained Timothy F. Burns, MD, PhD. “We have very good EGFR inhibitors,” said Burns. “When patients…

*January 2021* Poziotinib, mobocertinib (TAK-788), and fam-trastuzumab deruxtecan-nxki (Enhertu) are among some of the agents that have positioned HER2 as a must-test alteration in newly diagnosed advanced lung cancer, explained Lecia V. Sequist, MD, MPH, who added that the specificity of antibody-drug conjugates (ADCs) could challenge the broad activity of TKIs as…

*January 2021* The treatment paradigms of early-stage and metastatic lung cancer have expanded significantly in recent years with the addition of immunotherapy and targeted therapy options, said Brendon Stiles, MD, who added that challenges regarding screening, molecular testing, and localized therapy remain areas of ongoing research. “I tend to be…

*January 2021* Atezolizumab (Tecentriq), durvalumab (Imfinzi), pembrolizumab (Keytruda), and nivolumab (Opdivo) have demonstrated improved survival in combination with etoposide and platinum (EP) in untreated extensive-stage small cell lung cancer (ES-SCLC), cementing checkpoint inhibition plus chemotherapy as a frontline standard, explained Yanyan Lou, MD, PhD. IMpower133 was the first phase 3…

*January 2021* The combination of osimertinib (Tagrisso) plus bevacizumab (Avastin) failed to result in a statistically significant improvement in progression-free survival (PFS) versus osimertinib alone in patients with advanced lung adenocarcinoma that harbored an EGFR T790M mutation, according to findings from a phase 2 trial published in JAMA Oncology. Results showed that the…

*January 2021* Osimertinib (Tagrisso) has a strong foothold as first-line therapy for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but resistance to the third-generation EGFR tyrosine kinase inhibitor is a major stumbling block. "Understanding osimertinib resistance mechanisms and currently available treatment options are essential to selecting optimal second-line…

*November 2020* Watch the EGFR Research Summit wrap up video. You can learn more at our EGFR Summit website – www.egfrsummit.com